Every Form 4 that West Pharm Svcs (WST) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow WST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WST filings page.
WEST PHARMACEUTICAL SERVICES INC SVP & Chief Financial Officer Robert W. McMahon reported vesting and settlement of restricted stock units on August 11, 2026. He exercised or converted RSUs into 7,149.205 shares of common stock, and 3,109.19 shares of common stock were delivered or withheld at $351.37 per share for payment of exercise price or tax liability. The remaining common shares from these RSU conversions were retained as direct holdings. The Rule 10b5-1 trading plan checkbox was not selected.
HAUGEN JANET BRUTSCHEA reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services Inc. director Janet Brutschea Haugen reported routine equity-based compensation. She received a grant of 46 Phantom Stock Units tied to common stock, increasing her phantom unit balance to 306.678 units. She also holds 2,113.010 shares of common stock directly, plus 791 restricted stock units and dividend equivalents that will vest in full on the date of the next annual shareholder meeting under the Deferred Compensation Plan for Outside Directors. Awards of phantom stock units are to be settled in shares of stock upon her termination as a director.
West Pharmaceutical Services senior vice president Shane Alden Campbell reported routine equity compensation activity involving restricted stock units that convert into common stock on a one-for-one basis. On May 12, 2026, he exercised 473.593 and 295.995 RSUs into common shares, while 134.927 and 84.329 shares were disposed of to cover tax liabilities. These transactions reflect derivative exercises and tax-withholding dispositions rather than open‑market buying or selling.
Pucci Paolo reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Paolo Pucci received an equity grant in the form of restricted stock units. He was awarded 791 units of common stock on the reported date, increasing his direct holdings to 11,854.297 shares.
The footnote explains that these restricted stock units will vest in full on the date of the next annual shareholder meeting and will then be distributed under the company’s Deferred Compensation Plan for Outside Directors. This is a compensation-related award rather than an open-market purchase.
WEST PHARMACEUTICAL SERVICES INC director receives stock award. Director Douglas A. Michels acquired 791 shares of common stock as a grant or award, recorded at a price of $0.00 per share, reflecting equity compensation rather than a market purchase.
These shares are in the form of restricted stock units that will vest in full on the date of the next annual shareholder meeting and will be distributable under the company’s Deferred Compensation Plan for Outside Directors. After this grant, Michels directly holds 46,495.55 shares of common stock.
Lockhart Stephen H reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Stephen H. Lockhart received an equity award of 791 shares of common stock. The award is structured as restricted stock units that will vest in full on the date of the next annual shareholder meeting. After this grant, he holds a total of 3,523.2615 shares directly. This is a compensation-related grant, not an open-market purchase or sale.
LAI GOLDMAN MYLA reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Myla Lai-Goldman received 791 shares of Common Stock as a grant. The award was made at no cash cost per share and increased her directly held position to 20,434.587 shares.
According to the footnote, these shares are in the form of restricted stock units that will vest in full on the date of the next annual shareholder meeting and will be distributed under the company’s Deferred Compensation Plan for Outside Directors.
Keller Deborah L reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Deborah L. Keller received a grant of 791 shares of common stock in the form of restricted stock units on May 4, 2026. These restricted stock units will vest in full on the date of the next annual shareholder meeting. After this award, she directly holds 11,560.479 shares of West Pharmaceutical Services common stock.
Joseph Molly reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Molly Joseph received a grant of 791 shares of common stock as restricted stock units. The award was granted at a price of $0.00 per share, reflecting equity compensation rather than an open-market purchase. After this grant, Joseph holds a total of 4,398.187 shares of West Pharmaceutical common stock. According to the disclosure, these restricted stock units will vest in full on the date of the next annual shareholder meeting, at which point they are expected to become fully owned shares, subject to any applicable plan terms.
HAUGEN JANET BRUTSCHEA reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Janet Brutschea Haugen received an equity award in the form of restricted stock units. She was granted 791 shares of common stock at no cash cost, increasing her directly held stake to 2,372.752 shares. The restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributed under the company’s Deferred Compensation Plan for Outside Directors, tying part of her compensation to future company performance.
FRIEL ROBERT F reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Robert F. Friel received a grant of 791 shares of common stock in the form of restricted stock units. The award carried a price of $0.00 per share as it is a compensation grant rather than an open-market purchase.
The restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributed under the Deferred Compensation Plan for Outside Directors. Following this award, Friel directly holds 5,512.97 shares of West Pharmaceutical Services common stock.
Feehery William F reported acquisition or exercise transactions in this Form 4 filing.
WEST PHARMACEUTICAL SERVICES INC director William F. Feehery received an equity award of 791 shares of common stock in the form of restricted stock units. The award was granted at no cash price and increases his directly held position to 32,519.345 shares.
The restricted stock units will vest in full on the date of the next annual shareholder meeting and will then be distributable under the company’s Deferred Compensation Plan for Outside Directors. This reflects routine director compensation rather than an open-market purchase or sale.
BUTHMAN MARK A reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services Inc. director Mark A. Buthman received an equity award of 791 shares of common stock. The shares were granted at a price of $0.00 per share as a form of compensation, not an open-market purchase.
These shares are in the form of restricted stock units that will vest in full on the date of the next annual shareholder meeting. After this grant, Buthman directly holds a total of 44,308.5494 shares of West Pharmaceutical common stock.
West Pharmaceutical Services senior vice president and chief HR officer Annette F. Favorite exercised stock options and sold shares of common stock. On April 27, she exercised options to acquire 2,817 shares at $83.47 per share and then sold 2,817 shares in an open-market transaction at a weighted average price of $305.2018 per share.
After these transactions, she directly holds 16,828.4906 shares of common stock and indirectly holds 4,966.6170 shares through a Non-Qualified Deferred Compensation Plan, showing she retains a meaningful equity stake in the company despite the net sale.
West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters exercised stock options for 896 shares of common stock at $173.22 per share and on the same day sold 896 shares in an open-market sale at a weighted average price of $300.6688. After these transactions, he directly holds 1,522.81 shares.
HAUGEN JANET BRUTSCHEA reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Janet Brutschea Haugen received a grant of 52 Phantom Stock Units tied to common stock. The units were valued at $250.64 per unit, bringing her total Phantom Stock Units to about 260.494 held directly.
Footnote disclosures state that Phantom Stock Units will be settled in shares of stock when she terminates service as a director. A separate line shows she directly holds 1,321.258 shares of common stock. Another footnote notes 1,071 restricted stock units and dividend equivalents that vest in full on the date of the next annual shareholder meeting.
West Pharmaceutical Services reported that SVP, General Counsel and Corporate Secretary Norman D. Finch Jr. received equity awards. He was granted 1,285 restricted stock units and 3,057 stock options, each with an exercise right to buy common shares. Both the restricted stock units and options vest in four equal annual installments beginning on March 1, 2027.
Green Eric Mark reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services reported that President, CEO and Board Chair Eric Mark Green received new equity awards. On March 1, 2026, he was granted 6,986 restricted stock units, each representing a contingent right to receive one share of WST common stock.
On the same date, he was also granted 16,630 stock options to buy WST common stock. Both the restricted stock units and the stock options vest in four equal annual installments beginning on March 1, 2027, tying the awards to multi‑year service and performance at the company.
Favorite Annette F reported acquisition or exercise transactions in this Form 4 filing.
WEST PHARMACEUTICAL SERVICES INC executive Annette F. Favorite, Sr. VP & Chief HR Officer, reported equity awards rather than open-market trades. She received 720 restricted stock units, each representing one share of WST common stock, and 1,712 stock options, all held directly. Both the restricted stock units and options vest in four equal annual installments beginning on March 1, 2027.
West Pharmaceutical Services senior vice president Shane Alden Campbell reported equity compensation grants consisting of restricted stock units and stock options. He acquired 1,131 restricted stock units, each representing the right to receive one share of West common stock, and 2,691 stock options with a right to buy West shares.
Both the restricted stock units and the stock options vest in four equal annual installments beginning on March 1, 2027, meaning the awards become exercisable or deliverable over time rather than all at once. These are non-cash, equity-based compensation awards and do not reflect any open-market stock purchases or sales.
McMahon Robert W. reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services granted its SVP & Chief Financial Officer, Robert W. McMahon, two equity awards. He received 3,082 restricted stock units, each representing the right to one share of common stock, and options for 7,337 shares. Both awards vest in four equal annual installments beginning on March 1, 2027.
Poussot Rodolphe Jean reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services senior vice president of Strategy & Corporate Development Rodolphe Jean Poussot received equity awards on March 1, 2026. He was granted 437 restricted stock units, each representing one share of common stock, and stock options for 1,040 shares. Both awards vest in four equal annual installments beginning on March 1, 2027.
Winters Chad reported acquisition or exercise transactions in this Form 4 filing.
WEST PHARMACEUTICAL SERVICES INC executive Chad Winters, VP and Chief Accounting Officer, reported equity awards on restricted stock units and stock options. He received 340 restricted stock units and 808 stock options as grants, both described as derivative securities with no cash paid per unit in these awards.
Each restricted stock unit represents a contingent right to receive one share of WST common stock. Both the restricted stock units and the stock options vest in four equal annual installments beginning on March 1, 2027, creating a multi-year, performance- and service-linked compensation structure for this officer.
WEST PHARMACEUTICAL SERVICES INC senior vice president Rodolphe Jean Poussot reported equity compensation activity involving restricted stock units and common shares. On February 20, 2026, he exercised 383.382 restricted stock units, which converted into the same number of common shares at no cash cost.
Following this conversion, his directly held common stock position increased, then 129.545 shares of common stock were automatically withheld at $241.12 per share to cover tax obligations, leaving 561.235 common shares held directly after the transactions. Footnotes state that restricted stock units convert into common stock on a one-for-one basis and reference an earlier grant of 1,143 units vesting in three equal annual installments.
West Pharmaceutical Services VP & Treasurer Charles Witherspoon reported equity award activity involving restricted stock units and common shares. On February 20, 2026, 60.220 restricted stock units converted into 60.220 shares of common stock on a one-for-one basis, increasing his directly held common shares to 1,429.966.
To cover tax obligations related to the vesting, 22.069 common shares were disposed of at $241.12 per share through a tax-withholding transaction, leaving him with 1,407.897 directly owned common shares. After the transaction, he also directly held 177.644 restricted stock units, which can convert into common stock in the future under the award terms.
West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters exercised restricted stock units into common stock and had shares withheld to cover taxes. On February 20, 2026, he converted 89.328 restricted stock units into the same number of common shares at $0.00 per share, increasing his direct common stock holdings to 1,552.994 shares. On the same date, 30.184 common shares were disposed of at $241.12 per share in a tax-withholding transaction, leaving him with 1,522.810 common shares directly owned. Footnotes state these restricted stock units convert to common stock on a one-for-one basis and relate to a prior grant that vests in four equal annual installments.
West Pharmaceutical Services senior vice president Rodolphe Jean Poussot reported equity compensation activity involving restricted stock units and common shares. He acquired 82.299 common shares through the exercise or conversion of restricted stock units, which convert into common stock on a one-for-one basis.
Following this conversion, 27.809 common shares were disposed of at 248.26 per share to cover tax obligations through a tax-withholding disposition, rather than an open-market sale. After these transactions, his direct common stock holdings totaled 307.398 shares, and he held 247.899 restricted stock units directly. A prior grant of 329 restricted stock units vests in four equal annual installments, including dividend equivalents.
West Pharmaceutical Services VP & Treasurer Charles Witherspoon reported two stock transactions in company common stock. He acquired 115.910 shares at a stated price of $0.0000, representing shares issued from performance stock units that vested for the 2023–2025 performance period.
On the same date, 41.519 shares were disposed of at $243.1900 per share to cover tax obligations through share withholding, rather than an open-market sale. After these transactions, he directly owned 1,369.746 shares of West Pharmaceutical Services common stock.
West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters reported equity-related transactions involving company common stock. On February 17, 2026, he acquired 149.684 shares at a price of $0.00 per share as a grant or award. A footnote explains these shares resulted from performance stock units for the 2023–2025 performance period that vested and became payable on that date.
On the same date, Winters disposed of 50.579 shares at $243.19 per share to cover tax liabilities through share withholding, rather than an open-market sale. After these transactions, he directly owned 1,462.103 common shares.
West Pharmaceutical Services President and CEO Eric Mark Green reported several equity-related transactions. On February 17, 2026, he acquired 4,418.771 shares of common stock as a grant. On February 18, 2026, 1,318.810 restricted stock units, stemming from 2023–2025 performance stock units, converted into common stock on a one-for-one basis. To cover tax obligations, he disposed of 1,305.382 shares at $243.19 and 573.551 shares at $248.26. Following these transactions, he directly owned 175,160.6588 common shares and indirectly held 257.375 shares through a Non-Qualified Deferred Compensation Plan.
West Pharmaceutical Services senior vice president and chief HR officer Annette F. Favorite reported multiple equity transactions. On February 17, 2026, she acquired 441.957 shares of common stock through a grant or award and had 150.443 shares withheld to cover tax obligations. On February 18, 2026, she exercised 135.491 restricted stock units, converting them into the same number of common shares, with 35.757 shares withheld for taxes at prices of $243.1900 and $248.2600 per share, respectively. After these direct transactions, she held 17,374.4904 common shares directly and 4,962.0000 shares indirectly through a Non-Qualified Deferred Compensation Plan. Footnotes state that performance stock units from the 2023-2025 period vested and that restricted stock units convert into common stock on a one-for-one basis.
West Pharmaceutical Services SVP & CFO Robert W. McMahon reported equity award activity on February 11, 2026. He converted 4,230.525 restricted stock units into the same number of common shares at an exercise price of $0.
To cover tax obligations, 1,250.034 common shares were withheld at $246.16 per share, leaving 2,980.491 common shares held directly after the transaction. He also reported 8,462.052 restricted stock units remaining outstanding following these events.
West Pharmaceutical Services director reports equity awards and holdings. Director Janet Haugen reported beneficial ownership of 1,320.262 shares of West Pharmaceutical common stock, which includes 1,071 restricted stock units and related dividend equivalents that will vest in full on the date of the next annual shareholder meeting under the Deferred Compensation Plan for Outside Directors.
She also acquired 46 phantom stock units on 12/31/2025, each linked to one share of common stock at a reference price of $275.14, increasing her total phantom stock units to 208.3. These phantom units are to be settled in shares of stock when she terminates service as a director.
West Pharmaceutical Services executive Norman D. Finch, Jr., who serves as SVP, General Counsel & Corporate Secretary, reported equity awards in the company’s stock. On December 8, 2025, he received 192 restricted stock units, each representing a right to receive one share of common stock. This award is scheduled to vest in four equal installments beginning December 8, 2026, providing a staggered long-term incentive.
On the same date, Finch also received a stock option covering 459 shares of West Pharmaceutical common stock at an exercise price of $269.08 per share, with an expiration date of December 8, 2035. Both the RSUs and the option are reported as directly owned and reflect standard equity-based compensation for a senior officer.
Janet Brutschea Haugen, a director of West Pharmaceutical Services, Inc. (WST), reported transactions dated 09/30/2025. The Form 4 discloses a disposition of 1,319.348 shares of Common Stock and the acquisition of 48 Phantom Stock Units on the same date. The filing shows 162.161 shares reported as beneficially owned following the reported derivative transaction. Footnotes state the 1,071 restricted stock units and dividend equivalents underlying part of the position will vest in full at the next annual shareholder meeting and be distributable under the Deferred Compensation Plan for Outside Directors, and that phantom stock units are settled by delivery of shares upon the reporting person’s termination as a director. The form is signed by an agent on behalf of Ms. Haugen on 10/02/2025.